Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation

American Journal of Cardiology

Volumn 110, Issue 3, 2012, Pages 453-460

  Miller, Corey S ^a,c   Grandi, Sonia M ^a   Shimony, Avi ^a,b,d   Filion, Kristian B ^a   Eisenberg, Mark J ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; ATECEGATRAN METOXIL; DABIGATRAN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; EMBOLISM; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THIOPHENES; WARFARIN;

EID: 84863981277     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.03.049     Document Type: Review

References (27)

1. B.I. Eriksson, D.J. Quinlan, J.I. Weitz Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development Clin Pharmacokinet 48 2009 1 22
2. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, H.R. Al-Khalidi, J. Ansell, D. Atar, A. Avezum, M.C. Bahit, R. Diaz, J.D. Easton, J.A. Ezekowitz, G. Flaker, D. Garcia, M. Geraldes, B.J. Gersh, S. Golitsyn, S. Goto, A.G. Hermosillo, S.H. Hohnloser, J. Horowitz, P. Mohan, P. Jansky, B.S. Lewis, J.L. Lopez-Sendon, P. Pais, A. Parkhomenko, F.W. Verheugt, J. Zhu, L. Wallentin Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
3. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P.A. Reilly, E. Themeles, J. Varrone, S. Wang, M. Alings, D. Xavier, J. Zhu, R. Diaz, B.S. Lewis, H. Darius, H.C. Diener, C.D. Joyner, L. Wallentin Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
4. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, G. Breithardt, J.L. Halperin, G.J. Hankey, J.P. Piccini, R.C. Becker, C.C. Nessel, J.F. Paolini, S.D. Berkowitz, K.A. Fox, R.M. Califf Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
5. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, J.P. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, D. Moher The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med 6 2009 e1000100
6. H.C. Diener Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation: pooled analysis from the SPORTIF III and V studies Cerebrovasc Dis 21 2006 279 293
7. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
8. Higgins JPT, Altman DG, Sterne JAC, eds. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011). Available at: http://www.cochrane-handbook.org.
9. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, P.A. Reilly, L. Wallentin Newly identified events in the RE-LY trial N Engl J Med 363 2010 1875 1876
10. M.D. Ezekowitz, S. Connolly, A. Parekh, P.A. Reilly, J. Varrone, S. Wang, J. Oldgren, E. Themeles, L. Wallentin, S. Yusuf Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran Am Heart J 157 2009 805 810
11. S.J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, S. Yusuf Challenges of establishing new antithrombotic therapies in atrial fibrillation Circulation 116 2007 449 455
12. C. van Walraven, A. Jennings, N. Oake, D. Fergusson, A.J. Forster Effect of study setting on anticoagulation control: a systematic review and metaregression Chest 129 2006 1155 1166
13. United States Food and Drug Administration FDA approves Pradaxa to prevent stroke in people with atrial fibrillation http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm230241.htm Accessed November 30, 2011
14. United States Food and Drug Administration FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm Accessed November 30, 2011
15. J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, G. Palareti Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest 133 2008 160S 198S
16. D.K. Wysowski, P. Nourjah, L. Swartz Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action Arch Intern Med 167 2007 1414 1419
17. J.I. Weitz, S.J. Connolly, L. Patel, D. Salazar, S. Rohatagi, J. Mendell, H. Kastrissioss, J.Q. Lin, S. Kunitada Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation J Thromb Haemost 104 2010 633 641
18. N. Chung, H.K. Jeon, L.M. Lien, W.T. Lai, H.F. Tse, W.S. Chung, T.H. Lee, S.A. Chen Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation J Thromb Haemost 105 2011 535 545
19. C.T. Ruff, R.P. Giugliano, E.M. Antman, S.E. Crugnale, T. Bocanegra, M. Mercuri, J. Hanyok, I. Patel, M. Shi, D. Salazar, C.H. McCabe, E. Braunwald Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation- Thrombolysis In Myocardial Infarction Study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 2010 635 641
20. S. Ogawa, Y. Shinohara, K. Kanmuri Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation The ARISTOTLE J study Circ J 75 2011 1852 1859
21. G.Y.H. Lip, L.H. Rasmussen, S.B. Olsson, E.C. Jensen, A.L. Persson, U. Eriksson, K.F.C. Wahlander, C. Steering Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists Eur Heart J 30 2009 2897 2907
22. S.B. Olsson, L.H. Rasmussen, A. Tveit, E. Jensen, P. Wessman, S. Panfilov, K. Wahlander Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation J Thromb Haemost 103 2010 604 612
23. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, H. Eriksson, D. Baanstra, J. Schnee, S.Z. Goldhaber, R.-C.S. Grp Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism N Engl J Med 361 2009 2342 2352
24. H. Buller, D. Deitchman, M. Prins, A. Segers, I. Botticelli Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis The Botticelli DVT dose-ranging study J Thromb Haemost 6 2008 1313 1318
25. EINSTEIN Investigators Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
26. E.M. Hylek, C. Evans-Molina, C. Shea, L.E. Henault, S. Regan Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 115 2007 2689 2696
27. K.P. Cabral, J. Ansell, E.M. Hylek Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification J Thromb Haemost 9 2011 441 449